Absci stock gets slammed by macro conditions, rising interest rates


The biotech sector is taking a beating, since such valuations tend to be based on future revenue.

Previous First monkeypox case is detected in Oregon
Next Seattle health care data startup Opala names Premera Blue Cross exec as CEO